Olmesartán/Hidroclorotiazida Aurovitas (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartán/Hidroclorotiazida Aurovitas, is an angiotensin II receptor blocker (ARB) presented as a oral tablet for systemic use. It treats hypertension, often in combination with a diuretic, and is indicated for adults.

GNH USA supplies Olmesartán/Hidroclorotiazida Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/hydrochlorothiazide is used in the management of cardiovascular conditions that involve fluid retention and elevated vascular resistance. - Hypertension: low‑blood pressure control in patients requiring combined ARB and diuretic therapy. - Congestive heart failure: adjunctive treatment to reduce preload and afterload. - Edema associated with renal or hepatic disease: promotes diuresis and lowers blood pressure. - Diabetic nephropathy: helps protect renal function by controlling hypertension.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe electrolyte imbalance - Angio‑edema - Liver function abnormalities - Blood dyscrasias such as agranulocytosis

Patients should be evaluated for potential risks before initiating therapy and monitored regularly. - Renal impairment: adjust dose and monitor kidney function. - Hepatic disease: use with caution, monitor liver enzymes. - Electrolyte balance: check serum potassium and sodium regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid unless clearly needed. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/hydrochlorothiazide may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyperkalemia. - Aliskiren (in diabetic patients): increased risk of renal dysfunction. - NSAIDs (high‑dose or chronic use): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase serum lithium levels. - Antidiabetic agents: enhanced hypoglycaemic effect. - ACE inhibitors or other ARBs: additive risk of hypotension and renal impairment. - Antacids containing aluminium or magnesium: may reduce absorption of olmesartan.